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Light Forge: A Microfluidic DNA Melting-based
Tuberculosis Test
Ian M. Mbano,a*,† Tawanda Mandizvo,a*,† Jerome Rogich,b Tafara T.R. Kunota,a
Jared S. Mackenzie,a Manormoney Pillay,c and Frederick K. Balagadde´a
Background: There is a well-documented lack of rapid, low-cost tuberculosis (TB) drug resistance diagnostics in
low-income settings across the globe. It is these areas that are plagued with a disproportionately high disease bur-
den and in greatest need of these diagnostics.
Methods: In this study, we compared the performance of Light Forge, a microfluidic high-resolution melting
analysis (HRMA) prototype for rapid low-cost detection of TB drug resistance with a commercial HRMA device, a
predictive “nearest-neighbor” thermodynamic model, DNA sequencing, and phenotypic drug susceptibility testing
(DST). The initial development and assessment of the Light Forge assay was performed with 7 phenotypically drug
resistant strains of Mycobacterium tuberculosis (M.tb) that had their rpoB gene subsequently sequenced to confirm
resistance to Rifampin. These isolates of M.tb were then compared against a drug-susceptible standard, H37Rv.
Seven strains of M.tb were isolated from clinical specimens and individually analyzed to characterize the unique
melting profile of each strain.
Results: Light Forge was able to detect drug-resistance linked mutations with 100% concordance to the sequenc-
ing, phenotypic DST and the “nearest neighbor” thermodynamic model. Researchers were then blinded to the
resistance profile of the seven M.tb strains. In this experiment, Light Forge correctly classified 7 out of 9 strains as
either drug resistant or drug susceptible.
Conclusions: Light Forge represents a promising prototype for a fast, low-cost diagnostic alternative for detec-
tion of drug resistant strains of TB in resource constrained settings.
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INTRODUCTION
Tuberculosis (TB) is a deadly infectious disease
with 1.6 million deaths reported in 2017 (1). The
highest disease burden is seen in Africa and
South East Asia, low income regions, often with
poor healthcare delivery (2). The inability to control
infectious diseases adequately in these areas is
rooted in poor diagnosis and treatment. In TB, this
leads to increased infectivity, transmission, mor-
bidity, and mortality. Further compounding this
problem is the significant rise in the number of
drug-resistant strains of Mycobacterium tuberculo-
sis (M.tb), which are associated with higher mor-
bidity and mortality rates (3). It would be possible
to provide more efficient healthcare delivery by in-
creasing access to more economical diagnostic
devices. If M.tb infection and drug resistance pro-
files can be detected at a significantly lower cost
to public health systems, treatment would be initi-
ated earlier, with a substantial attainable decrease
in disease incidence (4). Unfortunately, despite in-
creased academic and commercial interest in
point-of-care diagnostics, few commercially avail-
able devices have managed to effectively deliver
to this underserved demographic.
Creating diagnostics within this context requires
an adept appreciation of the unique challenges
and limitations in the development, production,
and marketing of a diagnostic test for the develop-
ing world (5). Notably, the most important consid-
erations are device affordability and turnaround
time (6). Microfluidic technology can reduce the
cost of diagnosis by precisely manipulating minute
fluid volumes in parallel, thereby reducing the
overall consumption of reagents whilst increasing
diagnostic throughput. Engineering and refining
these fine networks of micro-plumbing allows inte-
gration of many functional components onto a
single device (7). A sample can be partitioned into
several independent fluid circuits in an efficient
manner, allowing multiple assays to be carried out
in parallel with minimal end-user intervention.
Another cost saving strategy for TB diagnostic devi-
ces is the utilization of high-resolution melting
analysis (HRMA), a post polymerase chain reaction
(PCR) method used to detect single nucleotide poly-
morphisms (SNPs) (8). It has the advantage of being
a single step as well as a closed tube assay that
allows for a rapid and reliable examination of PCR
product. This method has been used to detect
drug-resistant M.tb, with performance metrics com-
parable to the “gold standard” M.tb phenotypic
drug susceptibility testing (9, 10). HRMA has been
reported to cost USD $0.30 per reaction, but per-
forming it at volumes consistent with microfluidics
will reduce reagent costs by approximately 1,000
(11). We leveraged the efficiency and simplicity
afforded by a microfluidics platform with the simple,
linear workflow of HRMA to create Light Forge, a
functional and foundational blueprint for a low-cost
TB diagnostic for resource-limited settings.
In this study, we address the following research
questions: (1) Are the performance characteristics
IMPACT STATEMENT
The information presented in this study is primarily positioned to benefit TB-infected individuals from re-
source limited regions such as Sub-Saharan Africa and South East Asia where affordable and accessible
diagnostics are required. The evidence presented in this manuscript illustrates that combining DNA-melting
analysis with microfluidics can be a foundational formulation for a diagnostic that will be cheap, parallel,
and accessible in various clinical settings.
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of Light Forge comparable to a commercial HRMA
device, phenotypic drug susceptibility testing,
a predictive nearest-neighbor thermodynamic
model, and Sanger sequencing? (2) Can Light
Forge provide similar specificity to traditional
Sanger sequencing when blinded samples are an-
alyzed? To answer these questions, we obtained
seven rifampicin-resistant strains with known
mutations in the rifampicin (RIF) resistance deter-
mining region (RRDR) rpoB. Custom primers were
designed and the amplicons were melted to quan-
tify the melting temperature compared to H37Rv.
RIF resistance was selected as an appropriate tar-
get as sequence aberrations in and around the
81bp fragment of the RRDR accounting for 95%
of TB drug resistant cases (12, 13). A similar ap-
proach was adopted for the subsequent blinded
phase of the study.
MATERIALS ANDMETHODS
Mycobacteria tuberculosis Isolates
Eight DNA samples were used to develop the
assay for subsequent experiments. These were
obtained from 7 rifampicin-resistant laboratory
strains (Kzn605, R35, R271, Tkk-01-0039, Tkk-01-
0043, Tkk-01-0050, Tkk-01-0062), and H37Rv, used
as a drug-susceptible standard throughout the
study. The strains were sourced from Medical
Microbiology, School of Laboratory Medicine and
Medical Sciences at the Nelson R. Mandela School
of Medicine (Durban, South Africa) and Dr. Alex
Pym’s laboratory at the African Health Research
Institute (AHRI) (Durban, South Africa). The pheno-
typic drug-susceptibility profile of all the test
strains confirmed rifampicin resistance.
To further validate the performance of the as-
say, genomic DNA from 9 clinical M. tuberculosis
isolates (Tkk-01-0011, Tkk-01-0030, Tkk-01-0032,
Tkk-01-0061, Tkk-01-0078, Tkk-03-0082, Tkk-04-
0006, Tkk-04-0030, Tkk-04-0048) were also sourced
from Dr. Alex Pym’s laboratory at AHRI. The drug
susceptibility profile of each of these strains was
revealed after the Light Forge blinded study was
concluded.
DNA Extraction
DNA was extracted from heat-killed cultures us-
ing the hexadecyltrimethylammonium bromide
(CTAB) method (14).
Sanger Sequencing of the rpoB Gene Region
PCR amplicons of the rpoB gene for each strain
were sequenced by Inqaba Biotech Industries, us-
ing primer sets identical to the primers in the
high-resolution melting (HRMA) assay (Table 1).
Real-Time PCR and High-Resolution Melting
Analysis (HRMA) with Light CyclerVR96
Polymerase chain reaction (PCR) was performed
by first preparing a master mix through adding
25 mL of 2X XtremeTM Buffer (Novagen), 10 mL of
dNTPs (Novagen, ), 5ml of LC Green (Idaho
Technology Inc.), 0.3 mM of each Forward and
Reverse primer, 1 mL of KOD XtremeTM Hot Start
DNA polymerase (Novagen, Toyobo) and 5 mL of
template DNA containing 200ng of the DNA in a fi-
nal volume of 50 mL. PCR was performed using the
Light CyclerVR 96 (Roche Diagnostics, Switzerland).
The initial denaturation temperature was 95 C for
300 s, followed by 35 cycles of 95 C for 10 s, 60 C
for 10 s, 72 C for 10 s (fluorescence readout step).
A nontemplate control (NTC) was included in all
experiments, in which PCR Grade water (Life
Technologies) was substituted for the DNA
template.
For the HRMA, the following profile was used:
95 C for 60 s, 40 C for 60 s, 65 C for 1 s then at a
0.07 C/s ramp rate, acquiring 15 readings every
degree until 97 C. Difference plots were gener-
ated using H37Rv as the baseline signal. The test
readings from the samples were then normalized
to this standard. The total reaction time was
70min.
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Light Forge Microfluidic Chip Design and
Fabrication
The Light Forge PCR microfluidic chip was fabri-
cated out of the silicone elastomer polydimethylsi-
loxane (PDMS) (General Electric RTV 615) using
multi-layer soft lithography, as described previ-
ously (16). Up to 20 independent PCR reactions
can run in parallel on each chip (Fig. S1).
Real-Time PCR and High-Resolution Melting
with Light Forge
The real-time PCR and HRMA steps on the chip
were captured using the Light Forge software,
which was developed in house by Dr. Frederick
Balagadde´. This software uses a feedback system
that allows acquisition of fluorescence signals at
easily programmable temperatures, whilst display-
ing the reaction progress.
The PCR master mix was prepared using 30 mL
of 2X XtremeTM Buffer (Novagen), 15 mL of dNTPs
(Novagen), 9 mL of LC Green (Idaho Technology
Inc.), 0.46mM of each primer (Life Technologies),
3 mL of KOD XtremeTM Hot Start DNA polymerase
(Novagen), 0.08%(v/v) 1% Tween 20, and 3 mL of
template DNA(6ng) to make a total volume of
75 mL. For the 20-reactor chip, 8 reactors were
used for H37Rv, 8 for the test strains (R35, Kzn
605). The final 4 reactors contained the nontem-
plate controls.
The thermal cycling was performed using a
G-STORM GS1 (Somerten) thermocycler modi-
fied to house the microfluidic device. The fluo-
rescence signal was acquired in real-time using
an Olympus MVX10 (New York) Macro zoom mi-
croscope (Fig. S2). The thermal profile was 99 C
for 8minutes, followed by 35 cycles of 99 C for
65 s, 60 C for 115 s, 74.5 C for 130 s. The
HRMA was performed by increasing the temper-
ature from 75 C to 94 C at a ramp rate of
0.5 C/s with 0.25 C increments for each step.
This resulted in a total reaction time of 180min
(Fig. S3).
Nearest-Neighbor (NN) Thermodynamic
Model
The data from our experiments were compared
to the theoretical relative melting temperature dif-
ferences predicted by the mathematical nearest-
neighbor (NN) thermodynamic model (17). This
model predicts the melting temperature (TM) of a
DNA strand based on the cumulative standard
enthalpies (DHo) and standard entropies (DSo) of
neighboring duplex base pairs as well as the total
oligonucleotide strand concentration (Ct ) as
shown by Equation 1 below.
TM ¼
Pi¼n1
i¼1 DH
o
Pi¼n1
i¼1 DSo þ ln Ct4
  273:15 (Eq. 1)
Using the sequencing information from Sanger
sequencing, the (DTM) between the reference
strain (H37Rv) and the test strains used for the ini-
tial evaluation were computed. This model was
also used to compute the expected (DTM) of the
blinded samples. The computed prediction error
of the NN model was 61.2 0C (18). The SNPs ob-
served in resistant strains of M.tb result in
Table 1. Primer sequences used for PCR amplification, Sanger sequencing and subsequent HRMA of
the rpoB gene’s region known to determine rifampicin resistance (15).
Primer Sequence
Annealing
temperature(C) Product size(bp)
Nucleotide
position
Accession
number
rpoB-F CGCGATCAAGGAGTTCTTC 65 118 2339 to 2357 L27989.1
rpob-R TGACAGACCGCCGGGCCC 2456 to 2439
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temperature deviations ranging from (<0.1 to
1.4 0C) (19). Thus, the model cannot be used for
predicting exact differences but remains useful in
predicting whether the SNPs lead to a positive or
negative DTM.
Statistical Analysis
A two-way t-test was used to evaluate the signifi-
cance of the differences, where a P value of 0.05
or less was considered statistically significant
(GraphPad Prism 7).
RESULTS
rpoB Gene Mutations in ClinicalM.tb Strains
Seven strains with rifampicin resistance and a
reference H37Rv wild-type strain (rifampicin sensi-
tive) were selected for the initial evaluation of the
Light Forge. The 118 bp rpoB gene target of each
of the isolates was Sanger-sequenced prior to
HRMA. All the 7 sequence variants demonstrated
SNPs associated with resistance to rifampicin. A
total of 5 sequence SNPs present in 7 strains were
identified, including Kzn 605 (533 T! C and 516 A
! G), R35 (533 T ! C), R271 (531C ! T), Tkk-01-
0062 (516 A! T), Tkk-01-0050 (526C! T), Tkk-01-
0043 (531C! T), and Tkk-01-0039 (526C! T).
Real-Time PCR and HRMA for Drug
Susceptibility Testing on Test Strains
The rpoB PCRs for 7 clinical strains were run on
the Light CyclerVR 96 and were compared to the
Light Forge system (using the microfluidic chip
shown in Fig. 1). Fig. 2 illustrates the fluorescence
imaging of the Light Forge reactors at the 1st (A)
and 25th (B) thermal cycles during real-time PCR.
The A panel in Fig. 2 is a fluorescent image at
60 C at the first PCR cycle, while the B panel is the
fluorescent image at 60 C after 25 PCR cycles.
Each color-coded chamber contains 1.5 nL vol-
ume of PCR master mix. This is a representative
layout using a clinical mutant isolate (Tkk-01-0050)
and the wild type reference control H37Rv used in
the subsequent experiments. The test strain was
amplified in 8 out of 20 reactors (red border), the
reference wild type strain (H37Rv) was amplified in
8 out of 20 reactors (blue border), while the non-
template controls were amplified in 4 of 20 reac-
tors (yellow border). At the end of the
amplification, the Light Forge analysis was immedi-
ately initiated to melt the amplicons and detect
mutations. Mutations were identified as melting
temperature (TM) deviations relative to H37Rv.
Each individual line indicates a melt-curve profile
for an individual reactor.
The real-time PCR and HRMA are graphically il-
lustrated in Fig. 3 a and b respectively. The
HRMA profiles of H37Rv were used as the stan-
dard to which the 7 clinical strains were then
compared. Mutant melting curves could be dis-
tinguished from the wild type melting curve in
the normalized graphs (Fig. 3b) but were best
differentiated in the negative 1st derivative plot
(-dRFU/dT) shown in Fig. 3c. The average melting
temperature was computed for both the test
strain and H37Rv as shown in Fig. 3d. There was
100% concordance of the results from Light
CyclerVR 96 and Light Forge.
Comparison of Light Forge HRMA with
Sanger Sequencing, Roche Light CyclerVR96
and the Nearest-Neighbor (NN) Model
This section refers to Fig. 4. The sequencing
data for Kzn 605 identified 2 positive class two
mutations 533 T ! C and 516 A ! G within the
rpoB region. The Light Forge system identified
these Kzn 605 SNPs as having a melting tempera-
ture difference (DTM) of 0.956 0.06 C. The Light
CyclerVR 96 detected a (DTM) of (0.6160.02 C).
The NN model predicted a positive (DTM ) of
þ1.88 C.
Sequencing the R35 isolate revealed the posi-
tive class one mutation 533 T ! C within the rpoB
region. Consistently, Light Forge detected a (DTM)
of (0.306 0.11 C). For the same strain, Light
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CyclerVR 96 detected a (DTM) of (0.2260.02 C). The
NN model predicted a melting temperature of þ
0.67 C.
Sequencing the R271 isolate revealed the pres-
ence of a negative class one SNP 531C! T within
the rpoB region. Light Forge detected a (DTM) of
0.2960.09 C. A (DTM) of 0.2360.03 C was
detected for the same strain using the Light
CyclerVR 96. Consistent with the two systems, the
NN model detected a (DTM) 0.23 C.
The Light Forge system detected a (DTM) of
(0.2260.05 C) when the Tkk-01-0062 isolate was
compared to the reference. Sequencing high
lighted the presence of (1 positive) or (a positive)
class four SNP 516A ! T. The Light CyclerVR 96
could not detect this SNP, shown by a (DTM) of
0.0136 0.02 C. A (DTM) of þ 0.20 C was pre-
dicted by the NN model.
When the Tkk-01-0050 isolate was run
in the Light CyclerVR 96 system, a (DTM) of
0.28 6 0.02 C was detected. This observation
was consistent with sequencing findings, which
denoted the presence of 1 negative energy class
one SNP 526C ! T. Light Forge detected a (DTM)
of 0.5260.08 C. The NN model predicted a
(DTM) of 0.84 C, comparable with both the Light
CyclerVR 96 and the Light Forge systems.
The sequencing data for the Tkk-01-0043 isolate
identified one negative energy class one SNP
531C! T. Light Forge system detected a (DTM) of
0.4860.09 C, whereas the Light CyclerVR 96 sys-
tem detected 0.2460.02 C as the (DTM). The
NN model predicted a melting temperature differ-
ence of 0.23 C.
Sanger sequencing the Tkk-01-0039 isolate iden-
tified 1 negative energy class one SNP 526C ! T.
Fig. 1. The Light Forge microfluidic chip. Optical micrograph of the Light Forge microfluidic chip/car-
tridge for real-time PCR and high-resolution melting analysis of amplified samples. Scale bar, 1mm.
The chip/cartridge is made up of an elastomeric transparent polymer called polydimethylsiloxane and
has 20 reactors, each linked to an independent input port. These reactors are 500mm long, 200 mm
wide, and 150 mm high, translating into a volume of 1.5 nL. The PCR master mix was loaded at 5psi until
the PCR chambers were full.
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Consistently, the Light Forge system detected a
(DTM) of 0.376 0.16 C when this isolate was
compared to the reference, whereas the Light
CyclerVR 96 system detected a (DTM) of
0.2660.02 C. The NN model predicted a melt-
ing temperature difference of 0.84 C, which
agreed with both the Light CyclerVR 96 and the
Light Forge systems.
Validation of Light Forge with Blinded
Samples
For further validation of the Light Forge assay, 9
blinded samples were analyzed. The (DTM) melt
temperature of the blinded samples was com-
pared to H37Rv. Four (44.4%) of the 9 blinded
isolates showed melting curve profiles that were
synonymous to that of H37Rv (Fig. 5). However, 5
(55.5%) of the 9 blinded isolates were distinguish-
able from the H37Rv melting curve profile. In com-
parison to the culture-based RIF-susceptibility test
(DST), Light Forge correctly identified 7 out of 9 of
the isolates with 71.43% sensitivity and 100% spe-
cificity. The discrepancy was noted for Tkk-04-
0048, which had a drug-susceptible profile on the
Light Forge system but showed resistance in cul-
ture, confirmed with sequencing by the presence
of a double mutation in the drug-resistance deter-
mining region of the rpoB. The isolate Tkk-01-0030
also showed discrepancy with a drug-susceptible
profile on the Light Forge but resistance in culture,
Fig. 2. DNA quantification and high-resolution melt analysis in Light Forge PCR reactors. The Light Forge
chip/cartridge imaging area is shown in greater detail, demonstrating the visual accumulation of fluo-
rescence signal (within each of the 20 reactors, linked to independent input ports) as the Light Forge
system performs real-time PCR and High-Resolution Melting Analysis. An increased fluorescence signal
intensity is demonstrated with an increase in PCR cycle number. Fluorescence images of Light Forge
PCR reactors of the 1st (a) and 25th (b) thermal cycles during real-time PCR. The reactors in the image
have been demarcated with color-coded boundaries depending on the genomic DNA amplified: drug-re-
sistant mutants [Tkk-01-0050 (526CfiT), red]; drug-susceptible strains (H37Rv, blue); and nontemplate
controls (yellow). The amount of double-stranded DNA in each reactor corresponds to the level of fluo-
rescence of LC Green—a reporter double-stranded DNA intercalating dye in the master mix. LC Green
binds specifically to double-stranded DNA and fluoresces brightly when it binds. Unless specified other-
wise, all images were taken during the 60 C step of each thermal cycle. We were detecting fluores-
cence—in real-time via a custom program that runs on a temperature feedback loop—at 470-520nm,
the emission wavelength range of the reporter double stranded DNA saturating dye LC Green.
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Fig. 3. The real-time PCR and HRMA data from the Light Forge system testing the rpoB gene of the [Tkk-
01-0050 (526CfiT)] clinical strain. (a) Real-time PCR amplification curves for the rpoB region. These data
were all acquired simultaneously using the Light Forge microfluidic chip. For each reactor, a single
data point was acquired during the 60 C step. The relative fluorescence units (RFUs) corresponding to
the concentration of double-stranded DNA was plotted against the PCR cycle number. Eight real-time
amplification curves for drug-resistant [Tkk-01-0050 (526CfiT)] mutant strain are shown in red, 8 curves
for the drug-susceptible controls strains (H37Rv) in blue and four curves of the no template control
reactors in black. Both drug-susceptible control and drug-resistant mutant strain reactors increased
by more than 0.15 RFUs to over 0.45 RFUs, whereas the amplification signal for the nontemplate con-
trols remained relatively suppressed. (b) Normalized high-resolution melt (HRM) curves for the rpoB
PCR amplicons of the drug-resistant mutant strain [Tkk-01-0050 (526CfiT), red] and the drug-susceptible
control strain (H37Rv, blue). (c) Negative first derivatives plots revealing the melt peaks. The melting
temperature (TM) of each strain was determined by taking the mean of the melt peak of every replicate
for each individual strain. The average melting temperature for the drug-susceptible strain TMðwild typeÞ
was 83.6060.06 C and that of the drug-resistant mutant TMðmutantÞ was 83.0860.05 C. The relative dif-
ference of the melt peaks of these strains (DTM) provides important clues to the nature of the mutation
in the drug-resistant genome. (d) Peak intensity as a function of melting temperature. The average
melting temperatures for the drug-resistant mutant (Tkk-01-0050, red circles) and drug-susceptible con-
trol (H37Rv, blue triangles) were 83.6060.06 C and 83.0860.05 C respectively. The melting tempera-
tures were independent of the maximum fluorescence intensity (double-stranded DNA concentration)
and thus independent of the amplification efficiency in each reactor.
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confirmed with sequencing by the presence of an
(A to T) change.
DISCUSSION
Detecting drug-resistant strains of TB remains vi-
tal for the timely clinical management of the disease,
with potential to significantly reduce transmission.
This proof of concept (POC) study details the design,
development and preliminary performance evalua-
tion of Light Forge, a microfluidic device to detect
RIF resistance linked mutations inM.tb.
In the initial phase of the study, 7 RIF-resistant
strains of M.tb were used to bench mark the
performance of Light Forge to the Roche Light
CyclerVR 96. As shown in Fig. 4, Light Forge showed
100% concordance with Sanger sequencing com-
pared to the 86% demonstrated by the Light
CyclerVR 96. The same trend was observed when
Light Forge was compared to the nearest neigh-
bor (NN) thermodynamic model. An interesting
observation from the panel was that the commer-
cial device did not detect the presence of the mu-
tation in the Tkk-01-0062 strain. This strain
harbored a class 4 transversion (516A! T), which
is difficult to detect as it results in a melting tem-
perature difference of less than 0.4 C (15). This
was consistent with a study that showed that
HRMA had diminished ability to detect trans
Fig. 4. Comparison of melting temperature differences from Light Forge and Roche Light CyclerVR96
HRMA systems alongside the NN thermodynamic model TM predictions. Relative melting temperature
differences of the rpoB amplicon among 7 RIF-resistant strains and the reference RIF-susceptible strain
H37Rv were plotted using data generated from Light Forge (red bars) and Light CyclerVR96 (blue bars).
The black bars represent the theoretical relative melting temperature differences predicted by the
nearest neighbor (NN) thermodynamic model. The Light Forge data is consistent with Light CyclerV
R
96
data as well as the theoretical model predictions. However, Light Forge successfully detected a low-en-
ergy class 4 mutation that eluded detection by Light CyclerV
R
96 despite the nearest neighbor (NN) ther-
modynamic model having predicted that the mutation is detectable.
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versions when the reaction volume increased 5-
fold (20). The higher sensitivity is achieved through
rapid heat transfer in microfluidic-based PCR due
to the small reaction mass and the higher surface
to volume ratio of the small reactor, leading to a
more uniform temperature distribution (21).
To circumvent subjectivity of the study (22), the
second phase of the experiments was performed
with the scientists blinded to the resistance profile
for all nine clinical isolates. Light Forge detected
the presence of mutations in 7/9 isolates as
shown in Fig. 5 (5 RIF-R and 3 RIF-S), when com-
pared to sequencing and drug susceptibility pro-
files. Two RIF-resistant strains, Tkk-04-0048 and
Tkk-01-0030, were erroneously detected as wild
type. Tkk-04-0048 contained double mutations at
positions (511 T! C and 516G! T). These muta-
tions were undetectable as the increase in melting
temperature due to the mutation at position 511
was offset by a decrease in melting temperature
Fig. 5. Precision and reproducibility comparisons of Light Forge phenotypic resistance prediction on
blinded TB clinical isolates using HRMA. These results were reproducible by two independent Light
Forge experiment repeats with very small standard deviations.
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by the mutation at position 516. This observation
is not unique to this study, as it has been reported
that co-occurrence of class 3 and 4 mutations
within the same amplicon leads to minimal melt-
ing temperature deviation (23). Tkk-01-0030 con-
tained a single mutation (526 A ! T). This specific
mutation was located between two cytosine (C)
nucleotides as shown in supplemental Fig. S4. The
mutation appears to lead to minimal deviation in
the melting temperature in comparison to H37Rv,
consistent with the observations that (A/T) trans-
version have miniscule impact on the melting pro-
file of the amplicons (24–26). As stated previously,
we speculate that reducing the volume of the
microfluidic reactors by between 5- to 20-fold
could potentially enhance the resolution power of
the HRMA assay.
Whilst Light Forge has the potential to contrib-
ute significantly to improving health care delivery
systems, particularly those in low income settings,
it has limitations arising from its design based on
molecular testing of TB and its reliance on micro-
fluidic technology. First, HRMA can detect melting
temperature aberrations that can be misinter-
preted as the presence of mutations, but which
do not confer any phenotypic drug resistance (in-
cluding silent mutations). Thus, the assay can erro-
neously predict that a strain with the mutation
(516G ! C) is drug resistant, contrary to its drug-
sensitive profile (27). A similar occurrence was
reported when a silent mutation at codon 514 of
the rpoB gene was misclassified as drug resistant
using a commercial genotyping kit (28). This is the
major reason why sequencing and DST remain
more precise tools for asserting clinical resistance
of strains (29). Nevertheless, with proper execu-
tion, Light Forge could be a useful tool for screen-
ing TB patients.
Light Forge was designed using principles
adopted from microfluidic large-scale integration
(MLSI), which allow for several hundred to
thousands of reactors on a single device (30).
Some limitations of this study are that few isolates
were used, and that only DNA from pure clinical
cultures but no primary specimens such as blood
or sputum were used. In addition, the assay would
have benefited from a comparison with the well-
established GeneXpert MTB/RIF Assay. However,
these limitations do not detract from the value
and significance of the POC Light Forge findings.
To our knowledge, the Light Forge chip represents
one of the few iterations that were performed at
nanoliter scale. There are several modifications
that can be incorporated into Light Forge to ad-
dress possible errors that could emanate from
heterogeneity of M.tb populations, which may be
the case if primary specimens are used. We, there-
fore, propose a future Light Forge platform that
interrogates a single copy of DNA in each reactor
by combining limiting dilution and MLSI to acquire
melting point data for each single genome ampli-
con. Further advancements are required for Light
Forge to transition from proof-of-concept to a
commercially viable product. The run time of
180min requires reduction to make it feasible in
the clinical setting, an improvement which will be
easily implemented with more robust hardware. It
is encouraging that several devices have com-
pleted the transition from the diagnostic develop-
ment pipeline to commercial point-of-care
microfluidic devices for tasks such as blood analy-
sis and nucleic acid quantification, as well as iden-
tification of pathogens such as M.tb (Cepheid’s
GeneXpert System) (31).
Light Forge successfully detected 14 out of 16
samples based on their drug-resistance profiles.
Whilst this is a positive step towards creating an
accurate low-cost test for TB drug resistance, the
assay needs to account for difficult-to-detect
mutations such as double mutations and silent
mutations, as well as work toward the final devel-
opment of a version ready for clinical testing.
Possible improvements include use of a 21 mega-
pixel camera, a fluorescent lamp, a thermal block,
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and a simple computer interface to create a cost-
sensitive device similar to that developed by
Hatch and colleagues (32). Creating a device that
is easy for an end user to operate will allow rapid
integration within affected countries. A simplistic
design will also reduce the cost of purchase and
maintenance of the device. Prior to implementa-
tion, Light Forge should be validated using a larger
number of isolates as well as biological specimens
from patients with and without HIV from different
geographical regions (33).
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Supplemental material is available at The Journal
of Applied Laboratory Medicine online.
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